 | • レポートコード：MRC2312MG14070 • 出版社/出版日：Market Monitor Global / 2023年12月 • レポート形態：英文、PDF、104ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医療 |
| Single User | ￥487,500 (USD3,250) | ▷ お問い合わせ |
| Enterprise User | ￥731,250 (USD4,875) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査レポートは次の情報を含め、世界のAAVベクター遺伝子治療市場規模と予測を収録しています。・世界のAAVベクター遺伝子治療市場：売上、2018年-2023年、2024年-2029年 ・世界のAAVベクター遺伝子治療市場：販売量、2018年-2023年、2024年-2029年 ・世界のトップ5企業、2022年 世界のAAVベクター遺伝子治療市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「AAV1」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。 AAVベクター遺伝子治療のグローバル主要企業は、uniQure、 Roche、 Novartis、 BioMarin Pharmaceutical、 Ferring Pharmaceuticals A/S、 CSL Behring LLC、 PTC Therapeutics, Inc.、 Pfizer Inc.などです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。 MARKET MONITOR GLOBAL（MMG）は、AAVベクター遺伝子治療のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。 【セグメント別市場分析】 世界のAAVベクター遺伝子治療市場：タイプ別、2018年-2023年、2024年-2029年 世界のAAVベクター遺伝子治療市場：タイプ別市場シェア、2022年 ・AAV1、AAV2、AAV8、その他 世界のAAVベクター遺伝子治療市場：用途別、2018年-2023年、2024年-2029年 世界のAAVベクター遺伝子治療市場：用途別市場シェア、2022年 ・デュシェンヌジストロフィー、血友病、網膜疾患、その他 世界のAAVベクター遺伝子治療市場：地域・国別、2018年-2023年、2024年-2029年 世界のAAVベクター遺伝子治療市場：地域別市場シェア、2022年 ・北米：アメリカ、カナダ、メキシコ ・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア ・アジア：中国、日本、韓国、東南アジア、インド ・南米：ブラジル、アルゼンチン ・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE 【競合分析】 また、当レポートは主要な市場参加者の分析を提供します。 ・主要企業におけるAAVベクター遺伝子治療のグローバル売上、2018年-2023年 ・主要企業におけるAAVベクター遺伝子治療のグローバル売上シェア、2022年 ・主要企業におけるAAVベクター遺伝子治療のグローバル販売量、2018年-2023年 ・主要企業におけるAAVベクター遺伝子治療のグローバル販売量シェア、2022年 さらに、当レポートは主要企業のプロファイルを提示します。 uniQure、 Roche、 Novartis、 BioMarin Pharmaceutical、 Ferring Pharmaceuticals A/S、 CSL Behring LLC、 PTC Therapeutics, Inc.、 Pfizer Inc. ************************************************************* ・調査・分析レポートの概要 AAVベクター遺伝子治療市場の定義 市場セグメント 世界のAAVベクター遺伝子治療市場概要 当レポートの特徴・ベネフィット 調査手法と情報源 ・世界のAAVベクター遺伝子治療市場規模 世界のAAVベクター遺伝子治療市場規模：2022年 VS 2029年 世界のAAVベクター遺伝子治療市場規模と予測 2018年-2029年 ・競争状況 グローバルトップ企業 売上ベースでのグローバルトップ企業 企業別グローバルでのAAVベクター遺伝子治療の売上 グローバルトップ3およびトップ5企業、2022年売上ベース グローバル企業のAAVベクター遺伝子治療製品タイプ グローバルにおけるティア1、ティア2、ティア3企業 ・タイプ別市場分析 タイプ区分：AAV1、AAV2、AAV8、その他 AAVベクター遺伝子治療のタイプ別グローバル売上・予測 ・用途別市場分析 用途区分：デュシェンヌジストロフィー、血友病、網膜疾患、その他 AAVベクター遺伝子治療の用途別グローバル売上・予測 ・地域別市場分析 地域別AAVベクター遺伝子治療市場規模 2022年と2029年 地域別AAVベクター遺伝子治療売上・予測 北米市場：アメリカ、カナダ、メキシコ ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア アジア市場：中国、日本、韓国、東南アジア、インド 南米市場：ブラジル、アルゼンチン 中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE ・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど） uniQure、 Roche、 Novartis、 BioMarin Pharmaceutical、 Ferring Pharmaceuticals A/S、 CSL Behring LLC、 PTC Therapeutics, Inc.、 Pfizer Inc. ... |
This research report provides a comprehensive analysis of the AAV Vector Gene Therapy market, focusing on the current trends, market dynamics, and future prospects. The report explores the global AAV Vector Gene Therapy market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of AAV Vector Gene Therapy, challenges faced by the industry, and potential opportunities for market players.
The global AAV Vector Gene Therapy market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The AAV Vector Gene Therapy market presents opportunities for various stakeholders, including Duchenne Dystrophy, Hemophilia. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in AAV Vector Gene Therapy market. Additionally, the growing consumer demand present avenues for market expansion.
The global AAV Vector Gene Therapy market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period.
Key Features:
The research report on the AAV Vector Gene Therapy market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the AAV Vector Gene Therapy market.
Market Overview: The report provides a comprehensive overview of the AAV Vector Gene Therapy market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., AAV1, AAV2), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the AAV Vector Gene Therapy market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the AAV Vector Gene Therapy market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the AAV Vector Gene Therapy market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the AAV Vector Gene Therapy market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the AAV Vector Gene Therapy market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the AAV Vector Gene Therapy market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for AAV Vector Gene Therapy, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the AAV Vector Gene Therapy market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
AAV Vector Gene Therapy market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
AAV1
AAV2
AAV8
Other
Market segment by Application
Duchenne Dystrophy
Hemophilia
Retinal Diseases
Other
Global AAV Vector Gene Therapy Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
uniQure
Roche
Novartis
BioMarin Pharmaceutical
Ferring Pharmaceuticals A/S
CSL Behring LLC
PTC Therapeutics, Inc.
Pfizer Inc.
Outline of Major Chapters:
Chapter 1: Introduces the definition of AAV Vector Gene Therapy, market overview.
Chapter 2: Global AAV Vector Gene Therapy market size in revenue and volume.
Chapter 3: Detailed analysis of AAV Vector Gene Therapy manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of AAV Vector Gene Therapy in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global AAV Vector Gene Therapy capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
1 Introduction to Research & Analysis Reports
1.1 AAV Vector Gene Therapy Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global AAV Vector Gene Therapy Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global AAV Vector Gene Therapy Overall Market Size
2.1 Global AAV Vector Gene Therapy Market Size: 2022 VS 2029
2.2 Global AAV Vector Gene Therapy Revenue, Prospects & Forecasts: 2018-2029
2.3 Global AAV Vector Gene Therapy Sales: 2018-2029
3 Company Landscape
3.1 Top AAV Vector Gene Therapy Players in Global Market
3.2 Top Global AAV Vector Gene Therapy Companies Ranked by Revenue
3.3 Global AAV Vector Gene Therapy Revenue by Companies
3.4 Global AAV Vector Gene Therapy Sales by Companies
3.5 Global AAV Vector Gene Therapy Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 AAV Vector Gene Therapy Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers AAV Vector Gene Therapy Product Type
3.8 Tier 1, Tier 2 and Tier 3 AAV Vector Gene Therapy Players in Global Market
3.8.1 List of Global Tier 1 AAV Vector Gene Therapy Companies
3.8.2 List of Global Tier 2 and Tier 3 AAV Vector Gene Therapy Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global AAV Vector Gene Therapy Market Size Markets, 2022 & 2029
4.1.2 AAV1
4.1.3 AAV2
4.1.4 AAV8
4.1.5 Other
4.2 By Type – Global AAV Vector Gene Therapy Revenue & Forecasts
4.2.1 By Type – Global AAV Vector Gene Therapy Revenue, 2018-2023
4.2.2 By Type – Global AAV Vector Gene Therapy Revenue, 2024-2029
4.2.3 By Type – Global AAV Vector Gene Therapy Revenue Market Share, 2018-2029
4.3 By Type – Global AAV Vector Gene Therapy Sales & Forecasts
4.3.1 By Type – Global AAV Vector Gene Therapy Sales, 2018-2023
4.3.2 By Type – Global AAV Vector Gene Therapy Sales, 2024-2029
4.3.3 By Type – Global AAV Vector Gene Therapy Sales Market Share, 2018-2029
4.4 By Type – Global AAV Vector Gene Therapy Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global AAV Vector Gene Therapy Market Size, 2022 & 2029
5.1.2 Duchenne Dystrophy
5.1.3 Hemophilia
5.1.4 Retinal Diseases
5.1.5 Other
5.2 By Application – Global AAV Vector Gene Therapy Revenue & Forecasts
5.2.1 By Application – Global AAV Vector Gene Therapy Revenue, 2018-2023
5.2.2 By Application – Global AAV Vector Gene Therapy Revenue, 2024-2029
5.2.3 By Application – Global AAV Vector Gene Therapy Revenue Market Share, 2018-2029
5.3 By Application – Global AAV Vector Gene Therapy Sales & Forecasts
5.3.1 By Application – Global AAV Vector Gene Therapy Sales, 2018-2023
5.3.2 By Application – Global AAV Vector Gene Therapy Sales, 2024-2029
5.3.3 By Application – Global AAV Vector Gene Therapy Sales Market Share, 2018-2029
5.4 By Application – Global AAV Vector Gene Therapy Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global AAV Vector Gene Therapy Market Size, 2022 & 2029
6.2 By Region – Global AAV Vector Gene Therapy Revenue & Forecasts
6.2.1 By Region – Global AAV Vector Gene Therapy Revenue, 2018-2023
6.2.2 By Region – Global AAV Vector Gene Therapy Revenue, 2024-2029
6.2.3 By Region – Global AAV Vector Gene Therapy Revenue Market Share, 2018-2029
6.3 By Region – Global AAV Vector Gene Therapy Sales & Forecasts
6.3.1 By Region – Global AAV Vector Gene Therapy Sales, 2018-2023
6.3.2 By Region – Global AAV Vector Gene Therapy Sales, 2024-2029
6.3.3 By Region – Global AAV Vector Gene Therapy Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America AAV Vector Gene Therapy Revenue, 2018-2029
6.4.2 By Country – North America AAV Vector Gene Therapy Sales, 2018-2029
6.4.3 US AAV Vector Gene Therapy Market Size, 2018-2029
6.4.4 Canada AAV Vector Gene Therapy Market Size, 2018-2029
6.4.5 Mexico AAV Vector Gene Therapy Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe AAV Vector Gene Therapy Revenue, 2018-2029
6.5.2 By Country – Europe AAV Vector Gene Therapy Sales, 2018-2029
6.5.3 Germany AAV Vector Gene Therapy Market Size, 2018-2029
6.5.4 France AAV Vector Gene Therapy Market Size, 2018-2029
6.5.5 U.K. AAV Vector Gene Therapy Market Size, 2018-2029
6.5.6 Italy AAV Vector Gene Therapy Market Size, 2018-2029
6.5.7 Russia AAV Vector Gene Therapy Market Size, 2018-2029
6.5.8 Nordic Countries AAV Vector Gene Therapy Market Size, 2018-2029
6.5.9 Benelux AAV Vector Gene Therapy Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia AAV Vector Gene Therapy Revenue, 2018-2029
6.6.2 By Region – Asia AAV Vector Gene Therapy Sales, 2018-2029
6.6.3 China AAV Vector Gene Therapy Market Size, 2018-2029
6.6.4 Japan AAV Vector Gene Therapy Market Size, 2018-2029
6.6.5 South Korea AAV Vector Gene Therapy Market Size, 2018-2029
6.6.6 Southeast Asia AAV Vector Gene Therapy Market Size, 2018-2029
6.6.7 India AAV Vector Gene Therapy Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America AAV Vector Gene Therapy Revenue, 2018-2029
6.7.2 By Country – South America AAV Vector Gene Therapy Sales, 2018-2029
6.7.3 Brazil AAV Vector Gene Therapy Market Size, 2018-2029
6.7.4 Argentina AAV Vector Gene Therapy Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa AAV Vector Gene Therapy Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa AAV Vector Gene Therapy Sales, 2018-2029
6.8.3 Turkey AAV Vector Gene Therapy Market Size, 2018-2029
6.8.4 Israel AAV Vector Gene Therapy Market Size, 2018-2029
6.8.5 Saudi Arabia AAV Vector Gene Therapy Market Size, 2018-2029
6.8.6 UAE AAV Vector Gene Therapy Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 uniQure
7.1.1 uniQure Company Summary
7.1.2 uniQure Business Overview
7.1.3 uniQure AAV Vector Gene Therapy Major Product Offerings
7.1.4 uniQure AAV Vector Gene Therapy Sales and Revenue in Global (2018-2023)
7.1.5 uniQure Key News & Latest Developments
7.2 Roche
7.2.1 Roche Company Summary
7.2.2 Roche Business Overview
7.2.3 Roche AAV Vector Gene Therapy Major Product Offerings
7.2.4 Roche AAV Vector Gene Therapy Sales and Revenue in Global (2018-2023)
7.2.5 Roche Key News & Latest Developments
7.3 Novartis
7.3.1 Novartis Company Summary
7.3.2 Novartis Business Overview
7.3.3 Novartis AAV Vector Gene Therapy Major Product Offerings
7.3.4 Novartis AAV Vector Gene Therapy Sales and Revenue in Global (2018-2023)
7.3.5 Novartis Key News & Latest Developments
7.4 BioMarin Pharmaceutical
7.4.1 BioMarin Pharmaceutical Company Summary
7.4.2 BioMarin Pharmaceutical Business Overview
7.4.3 BioMarin Pharmaceutical AAV Vector Gene Therapy Major Product Offerings
7.4.4 BioMarin Pharmaceutical AAV Vector Gene Therapy Sales and Revenue in Global (2018-2023)
7.4.5 BioMarin Pharmaceutical Key News & Latest Developments
7.5 Ferring Pharmaceuticals A/S
7.5.1 Ferring Pharmaceuticals A/S Company Summary
7.5.2 Ferring Pharmaceuticals A/S Business Overview
7.5.3 Ferring Pharmaceuticals A/S AAV Vector Gene Therapy Major Product Offerings
7.5.4 Ferring Pharmaceuticals A/S AAV Vector Gene Therapy Sales and Revenue in Global (2018-2023)
7.5.5 Ferring Pharmaceuticals A/S Key News & Latest Developments
7.6 CSL Behring LLC
7.6.1 CSL Behring LLC Company Summary
7.6.2 CSL Behring LLC Business Overview
7.6.3 CSL Behring LLC AAV Vector Gene Therapy Major Product Offerings
7.6.4 CSL Behring LLC AAV Vector Gene Therapy Sales and Revenue in Global (2018-2023)
7.6.5 CSL Behring LLC Key News & Latest Developments
7.7 PTC Therapeutics, Inc.
7.7.1 PTC Therapeutics, Inc. Company Summary
7.7.2 PTC Therapeutics, Inc. Business Overview
7.7.3 PTC Therapeutics, Inc. AAV Vector Gene Therapy Major Product Offerings
7.7.4 PTC Therapeutics, Inc. AAV Vector Gene Therapy Sales and Revenue in Global (2018-2023)
7.7.5 PTC Therapeutics, Inc. Key News & Latest Developments
7.8 Pfizer Inc.
7.8.1 Pfizer Inc. Company Summary
7.8.2 Pfizer Inc. Business Overview
7.8.3 Pfizer Inc. AAV Vector Gene Therapy Major Product Offerings
7.8.4 Pfizer Inc. AAV Vector Gene Therapy Sales and Revenue in Global (2018-2023)
7.8.5 Pfizer Inc. Key News & Latest Developments
8 Global AAV Vector Gene Therapy Production Capacity, Analysis
8.1 Global AAV Vector Gene Therapy Production Capacity, 2018-2029
8.2 AAV Vector Gene Therapy Production Capacity of Key Manufacturers in Global Market
8.3 Global AAV Vector Gene Therapy Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 AAV Vector Gene Therapy Supply Chain Analysis
10.1 AAV Vector Gene Therapy Industry Value Chain
10.2 AAV Vector Gene Therapy Upstream Market
10.3 AAV Vector Gene Therapy Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 AAV Vector Gene Therapy Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer